Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chengdu Wending Technology Development Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is distributed across a distinct examiner and a distinct art unit. The limited number of pending actions indicates a narrow prosecution pipeline for the company at this time. This centralized structure means that the company's entire patent strategy in this area is currently focused on a specific technical review process.
WELLS, LAUREN QUINLAN is identified as the busiest examiner for the portfolio, handling 1 pending office action. Because this examiner is responsible for the only pending matter, the company's immediate prosecution outcomes depend entirely on this interaction. This centralized workload simplifies the monitoring process for the current portfolio, as there are no competing actions or differing examiner styles to manage. Practitioners can dedicate resources to understanding the specific requirements of this examiner within the art unit involved. The data shows a direct correlation between the busiest examiner's workload and the total pending actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18107835 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC KIDNEY DISEASE | WELLS, LAUREN QUINLAN | 53d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18107835 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC KIDNEY DISEASE | WELLS, LAUREN QUINLAN | 1622 | §103DP | Final Rejection | 53d overdue | Pending | Feb 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial